Teucrium Soybean Fund vs Vir Biotechnology Inc. Common Stock — how do they compare? Teucrium Soybean Fund trades at $27.2 (market cap $43.28M), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Vir Biotechnology Inc. Common Stock is far larger — about 41.6× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is more actively traded (28,719 versus 1,782,836). Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Soybean Fund for 25 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SOYB | VIR | |
|---|---|---|
Market Cap | $43.28M | $1.80B |
Volume | 28,719 | 1,782,836 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $28.14 | $11.78 |
52-Week Low | $21.59 | $5.12 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | — | $1.36B |
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $27.33, down 0.51% today, with a bullish technical signal driven by moving averages. The stock is consolidating near key support at $27, with neutral oscillators indicating limited momentum. Recent news highlights potential catalysts from U.S.-China trade talks, which could boost soybean demand.
The outlook hinges on trade developments and commodity price trends, offering upside if diplomatic progress materializes. Risks include geopolitical tensions and commodity market volatility. Analyst sentiment appears cautiously optimistic, but fundamental data remains sparse for detailed assessment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →